Denali Therapeutics Inc (NASDAQ: DNLI) started the day on Wednesday, with a price increase of 4.66% at $16.16, before settling in for the price of $15.44 at the close. Taking a more long-term approach, DNLI posted a 52-week range of $14.56-$33.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 264.19%. Meanwhile, its Annual Earning per share during the time was -21.99%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -143.61%. This publicly-traded company’s shares outstanding now amounts to $138.39 million, simultaneously with a float of $115.02 million. The organization now has a market capitalization sitting at $2.30 billion. At the time of writing, stock’s 50-day Moving Average stood at $18.86, while the 200-day Moving Average is $20.50.
Denali Therapeutics Inc (DNLI) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Denali Therapeutics Inc’s current insider ownership accounts for 19.30%, in contrast to 76.41% institutional ownership. According to the most recent insider trade that took place on Apr 15 ’24, this organization’s Director sold 1,666 shares at the rate of 18.29, making the entire transaction reach 30,471 in total value, affecting insider ownership by 118,043. Preceding that transaction, on Apr 01 ’24, Company’s Director sold 92,500 for 20.50, making the whole transaction’s value amount to 1,896,250. This particular insider is now the holder of 47,341 in total.
Denali Therapeutics Inc (DNLI) Earnings and Revenue Records
Denali Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -143.61% and is forecasted to reach -2.53 in the upcoming year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Let’s observe the current performance indicators for Denali Therapeutics Inc (DNLI). It’s Quick Ratio in the last reported quarter now stands at 13.65. The Stock has managed to achieve an average true range (ATR) of 0.86. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.97.
In the same vein, DNLI’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.09, a figure that is expected to reach -0.69 in the next quarter, and analysts are predicting that it will be -2.53 at the market close of one year from today.
Technical Analysis of Denali Therapeutics Inc (DNLI)
If we take a close look at the recent performances of Denali Therapeutics Inc (NASDAQ: DNLI), its last 5-days Average volume was 1.1 million that shows plunge from its year to date volume of 1.18 million. During the previous 9 days, stock’s Stochastic %D was recorded 47.64% While, its Average True Range was 0.82.
Raw Stochastic average of Denali Therapeutics Inc (DNLI) in the period of the previous 100 days is set at 17.30%, which indicates a major fall in contrast to 35.96% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 42.05% that was lower than 78.78% volatility it exhibited in the past 100-days period.
